An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

MLA

Akifumi Kuwano, et al. “An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.” Cancer Diagnosis & Prognosis, vol. 3, no. 4, July 2023, pp. 468–74. EBSCOhost, https://doi.org/10.21873/cdp.10241.

APA

Akifumi Kuwano, Masayoshi Yada, Yoshiko Miyazaki, Kosuke Tanaka, Yuta Koga, Yoshihiro Ohishi, Akihide Masumoto, & Kenta Motomura. (2023). An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. Cancer Diagnosis & Prognosis, 3(4), 468–474. https://doi.org/10.21873/cdp.10241

Chicago

Akifumi Kuwano, Masayoshi Yada, Yoshiko Miyazaki, Kosuke Tanaka, Yuta Koga, Yoshihiro Ohishi, Akihide Masumoto, and Kenta Motomura. 2023. “An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.” Cancer Diagnosis & Prognosis 3 (4): 468–74. doi:10.21873/cdp.10241.